- Home
- QNCX vs DPRO Comparison
QNCX vs DPRO Comparison
Compare QNCX & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- DPRO
- Stock Information
- Founded
- QNCX 2012
- DPRO 1998
- Country
- QNCX United States
- DPRO Canada
- Employees
- QNCX N/A
- DPRO N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- DPRO Aerospace
- Sector
- QNCX Health Care
- DPRO Industrials
- Exchange
- QNCX Nasdaq
- DPRO Nasdaq
- Market Cap
- QNCX 85.9M
- DPRO 81.2M
- IPO Year
- QNCX 2019
- DPRO N/A
- Fundamental
- Price
- QNCX $1.60
- DPRO $5.22
- Analyst Decision
- QNCX Strong Buy
- DPRO Strong Buy
- Analyst Count
- QNCX 6
- DPRO 2
- Target Price
- QNCX $8.00
- DPRO $6.50
- AVG Volume (30 Days)
- QNCX 124.9K
- DPRO 1.4M
- Earning Date
- QNCX 11-12-2025
- DPRO 11-13-2025
- Dividend Yield
- QNCX N/A
- DPRO N/A
- EPS Growth
- QNCX N/A
- DPRO N/A
- EPS
- QNCX N/A
- DPRO N/A
- Revenue
- QNCX N/A
- DPRO $5,250,872.00
- Revenue This Year
- QNCX N/A
- DPRO $41.59
- Revenue Next Year
- QNCX N/A
- DPRO $132.11
- P/E Ratio
- QNCX N/A
- DPRO N/A
- Revenue Growth
- QNCX N/A
- DPRO 17.08
- 52 Week Low
- QNCX $0.69
- DPRO $1.63
- 52 Week High
- QNCX $2.45
- DPRO $7.31
- Technical
- Relative Strength Index (RSI)
- QNCX 47.89
- DPRO 58.63
- Support Level
- QNCX $1.56
- DPRO $4.28
- Resistance Level
- QNCX $1.65
- DPRO $4.86
- Average True Range (ATR)
- QNCX 0.07
- DPRO 0.35
- MACD
- QNCX 0.00
- DPRO 0.08
- Stochastic Oscillator
- QNCX 64.65
- DPRO 83.93
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.